Brown Adipose Tissue Activity Biomarkers in Energy Regulation

Abstract

Brown adipose tissue (BAT) has emerged as a pivotal organ in human energy regulation due to its capacity for thermogenesis and its potential role in combating metabolic diseases. The identification and validation of reliable biomarkers that reflect BAT activity are critical for advancing both research and clinical applications. This review synthesizes current evidence on BAT activity biomarkers, their mechanistic basis, and their clinical relevance in metabolic health, providing a comprehensive overview for healthcare professionals.

Introduction

Energy homeostasis is a finely tuned process influenced by various tissues and regulatory pathways, with BAT playing a central role in non-shivering thermogenesis. Unlike white adipose tissue (WAT), BAT dissipates chemical energy as heat, thus contributing to overall energy expenditure and metabolic health. Research into BAT activity, particularly the identification of robust activity biomarkers, has gained momentum due to the rising prevalence of metabolic diseases such as obesity and type 2 diabetes. This review addresses the current understanding of BAT activity biomarkers, their pathophysiological relevance, and implications for clinical practice.

Epidemiology / Disease Burden

The global escalation of obesity and metabolic syndrome has intensified interest in novel strategies for energy regulation. Epidemiological studies reveal that BAT activity is inversely correlated with body mass index (BMI), age, and the incidence of metabolic diseases. Although BAT was once believed to be limited to infants, positron emission tomography (PET) studies have demonstrated its functional presence in adults, with varying prevalence across populations. Reduced BAT activity is associated with higher metabolic risk, underscoring the burden of diseases linked to impaired thermogenesis and energy imbalance.

Pathophysiology

Browning of adipose tissue refers to the induction of BAT-like characteristics in WAT, characterized by multilocular lipid droplets and abundant mitochondria expressing uncoupling protein 1 (UCP1). BAT thermogenesis is primarily regulated by sympathetic nervous system activation and the release of norepinephrine, which stimulates UCP1-mediated proton leak and heat production. Several circulating factors, termed batokines, such as fibroblast growth factor 21 (FGF21), neuregulin 4 (NRG4), and irisin, have been implicated as potential biomarkers reflecting BAT activity. Additionally, metabolites including acylcarnitines and lipokines are being explored for their mechanistic links to BAT activation.

Risk Factors

Risk factors for reduced BAT activity include advancing age, increased adiposity, sedentary lifestyle, and certain genetic predispositions. Environmental factors, such as chronic exposure to warm temperatures, suppress BAT function, while cold exposure is a potent activator. Endocrine disorders, including hypothyroidism and polycystic ovary syndrome (PCOS), may also be associated with diminished BAT activity. Understanding these risk factors is essential for interpreting biomarker levels in clinical and research contexts.

Clinical Features

Clinically, increased BAT activity is associated with improved insulin sensitivity, enhanced lipid clearance, and lower risk of obesity-related complications. While BAT is not directly visualized in routine clinical practice, indirect features such as heightened resting energy expenditure and improved glucose tolerance may reflect underlying BAT thermogenesis. In rare cases, excessive BAT activity can contribute to cachexia in malignant diseases, emphasizing the need for context-specific interpretation of biomarker data.

Diagnosis

Assessment of BAT activity has traditionally relied on 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging, which, despite its sensitivity, is limited by cost, radiation exposure, and methodological complexity. As a result, there is growing interest in non-invasive, circulating biomarkers that can reliably indicate BAT activation. Candidate biomarkers include plasma levels of FGF21, NRG4, irisin, and specific lipid metabolites such as 12,13-diHOME. Measurement of these biomarkers, often in conjunction with cold exposure protocols, offers a promising avenue for both research and, potentially, clinical practice.

Treatment & Management

Pharmacological and lifestyle interventions aimed at enhancing BAT activity are under investigation as adjuncts in the management of obesity and metabolic disorders. Cold exposure, exercise, and certain dietary components (e.g., capsaicin, catechins) can activate BAT. Pharmacological agents such as β3-adrenergic agonists have shown efficacy in increasing BAT activity, as evidenced by biomarker and imaging studies. Monitoring BAT biomarkers may facilitate personalized therapeutic strategies and evaluation of treatment response.

Recent Advances / Emerging Therapies

Recent years have witnessed the discovery of novel batokines and lipid metabolites as potential biomarkers, including FGF21, NRG4, and 12,13-diHOME. Advances in omics technologies are enabling the identification of BAT-specific transcriptomic and proteomic signatures. Emerging therapies targeting BAT activation include gene editing, mitochondrial uncouplers, and small molecules modulating sympathetic outflow. Ongoing clinical trials are evaluating the utility of BAT biomarkers in predicting therapeutic outcomes and guiding individualized interventions.

Guideline Recommendations

While no formal guidelines exist specifically for BAT biomarker use, expert consensus emphasizes the integration of biomarker assessment with clinical and imaging data, particularly in research settings. The Endocrine Society and other relevant bodies advocate for further validation of BAT biomarkers before routine clinical implementation. Clinicians are encouraged to consider BAT activity in the broader context of metabolic risk assessment and to remain informed about evolving evidence and recommendations.

Conclusion

The identification and clinical application of BAT activity biomarkers represent a frontier in metabolic medicine. As research continues to elucidate the mechanisms and implications of BAT thermogenesis, these biomarkers hold promise for advancing understanding, diagnosis, and management of energy dysregulation in humans. Rigorous validation and standardization are essential for translating these insights into routine clinical practice, with the ultimate goal of improving outcomes in metabolic disease.